ibrance
Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer
January 15, 2020Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma
NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
November 28, 2019Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma
Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …
Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation
July 11, 2019Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma
Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …
FDA approves Pfizer’s Ibrance for advanced male breast cancer
April 5, 2019Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma
The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …
Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer
June 26, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma
Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …
NICE approves Novartis and Pfizer’s rival breast cancer drugs
November 16, 2017Sales and Marketing Kisqali, Novartis, Pfizer, biotech, drugs, ibrance, pharma, pharmaceutical
NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of …
Pfizer secures expanded approval for Ibrance
April 3, 2017Sales and Marketing Pfizer, ibrance
Pfizer has announced that FDA has approved its supplemental New Drug Application (sNDA) for Ibrance, meaning that the drug is …
Pfizer’s breast cancer drug gets EU approval
November 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Novartis, Pfizer, ibrance
Pfizer is celebrating the approval by the European Union of its breast cancer drug Ibrance, following a positive recommendation from …
Novartis breast cancer drug secures FDA fast-track status
November 1, 2016Manufacturing and Production, Sales and Marketing Novartis, Pfizer, ibrance, letrozole, riboclib
Novartis has announced that its product ribociclib (LEE011) has been granted fast-track review status as a first-line treatment of advanced …
Novartis’ new drug muscles in on Pfizer’s territory
October 10, 2016Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib
A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …
Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations
August 2, 2016Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results
Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …
Pfizer raised 100 US drug prices 1 January
January 12, 2016Manufacturing and Production, Sales and Marketing Allergan, Drug pricing, Lyrica, Pfizer, ibrance, tax inversion
Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January, in …
Pfizer breast cancer trial stopped following promising results
April 15, 2015Sales and Marketing ASCO, FDA, Pfizer, ibrance, palbociclib
Regulators have stopped a Phase III clinical trial of Pfizer’s Ibrance early after it demonstrated improved survival in women with …
Pfizer gets early approval for breast cancer drug
February 4, 2015Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib
The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …
